Search

Author/Creator Su, Xiaoxing

1. Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial. Issue 8 (1st December 2022)

Authors:
Jin, Shuiling; Zhao, Ruihua; Zhou, Chuang; Zhong, Qian; Shi, Jianxiang; Su, Chang; Li, Qinglong; Su, Xiaoxing; Chi, Huabin; Lu, Xu; Jiang, Guozhong; Chen, Renyin; Han, Jinming; Jiang, Miao; Qiao, Shishi; Liu, Jingjing; Song, Min; Song, Lijie; Du, Yabing; Chang, Zhiwei
Journal:
International journal of cancer
Issue:
Volume 152:Issue 8(2023)
Page Start:
1648
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Tracking the evolution of untreated high‐intermediate/high‐risk diffuse large B‐cell lymphoma by circulating tumour DNA. (19th October 2021)

Authors:
Zhang, Sicong; Zhang, Tingting; Liu, Hengqi; Zhao, Jing; Zhou, Haifei; Su, Xiaoxing; Liu, Xianming; Li, Lanfang; Qiu, Lihua; Qian, Zhengzi; Zhou, Shiyong; Gong, Wenchen; Meng, Bin; Ren, Xiubao; He, Jin; Wang, Xianhuo; Zhang, Huilai
Journal:
British journal of haematology
Issue:
Volume 196:Number 3(2022)
Page Start:
617
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗